8.0 regulatory
FDA Accepts NDA for Vepdegestrant by Arvinas Operations
8.0 regulatory
FDA Approves Glycerol Phenylbutyrate Application by Lupin
8.0 regulatory
FDA Approves Pregabalin Application ANDA219593 by Unichem
8.0 regulatory
FDA Approves Sitagliptin and Metformin Hydrochloride Combination
8.0 regulatory
FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer
8.0 regulatory
Resmed Issues Correction for Astral Ventilator Due to Electrical Component Failure
8.0 regulatory
FDA Approves Supplement for VEKLURY (Remdesivir) by Gilead Sciences
8.0 regulatory
FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094
8.0 clinical
Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise
8.0 regulatory
FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience
8.0 regulatory
Teva's Sugammadex Sodium Receives FDA Approval Status
8.0 regulatory
FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi
8.0 clinical
Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas
8.0 competitive
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
8.0 regulatory
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
8.0 regulatory
FDA Approves Sugammadex Sodium for Gland Pharma
8.0 clinical
Selinexor and Radiation Therapy Trial for DIPG and HGG Shows Promise
8.0 clinical
Mosunetuzumab shows promise in B-cell NHL beyond follicular lymphoma
8.0 clinical
CAFs Enhance Adenosine Production in NSCLC, Impeding T Cell Response
8.0 regulatory
FDA Grants Approval for Sugammadex Sodium under ANDA214368
8.0 regulatory
Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy
8.0 regulatory
Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA
8.0 regulatory
FDA Grants Priority Review for NUPLAZID Supplement NDA210793
8.0 regulatory
HPV Vaccine Hesitancy Among Female Students in China Increases Despite Improved Knowledge
8.0 clinical
Platelet-based delivery of fluorescein enhances sonodynamic therapy in glioblastoma
8.0 clinical
Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China
8.0 regulatory
Aficamten Approved by MHRA and Recommended by NICE for Heart Condition
8.0 clinical
DNA polymerase theta emerges as a promising target for cancer therapy
8.0 fallback
HPV Vaccination Challenges and Strategies in WHO South-East Asia Region Identified
8.0 clinical
Novel Rh-catalysed method yields potent antitumor phenanthridinone derivatives
8.0 regulatory
FDA Approves Afamitresgene Autoleucel for Synovial Sarcoma, Highlighting TCR Therapy Advances
8.0 clinical
Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated
8.0 regulatory
European Commission Approves Pfizer-BioNTech XFG-adapted COVID-19 Vaccine for 2026-2027
9.0 regulatory
CHMP recommends EU approval of Roche’s Susvimo for nAMD treatment
9.0 regulatory
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
9.0 regulatory
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
9.0 regulatory
FDA Approves Veklury as First Treatment for COVID-19
9.0 competitive
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
9.0 clinical
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
9.0 regulatory
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
9.0 regulatory
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
9.0 regulatory
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
9.0 clinical
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
9.0 regulatory
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
9.0 regulatory
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
9.0 regulatory
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
9.0 clinical
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
9.0 regulatory
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
9.0 regulatory
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
9.0 regulatory
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer